|
[1]
|
Wang O, Hu Y, Gong S, et al. A survey of outcomes and management of patients post fragility fractures in China[J]. Osteoporos Int, 2015, 26: 2631-2640. doi: 10.1007/s00198-015-3162-6 |
|
[2]
|
Hu J, Zheng W, Zhao D, et al. Health-related quality of life in men with osteoporosis: a systematic review and meta-analysis[J]. Endocrine, 2021, 74: 270-280. doi: 10.1007/s12020-021-02792-0 |
|
[3]
|
Wang L, Yu W, Yin X, et al. Prevalence of Osteoporosis and Fracture in China: The China Osteoporosis Prevalence Study[J]. JAMA Netw Open, 2021, 4: e2121106. doi: 10.1001/jamanetworkopen.2021.21106 |
|
[4]
|
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2022)[J]. 中华骨质疏松和骨矿盐疾病杂志, 2022, 15: 573-611. https://www.cnki.com.cn/Article/CJFDTOTAL-ZDLS202303004.htm |
|
[5]
|
中国疾病预防控制中心, 中华医学会骨质疏松和骨矿盐疾病分会. 中国骨质疏松症流行病学调查报告(2018)[M]. 北京: 人民卫生出版社, 2021. |
|
[6]
|
Nayak S, Edwards DL, Saleh AA, et al. Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density[J]. Osteoporos Int, 2015, 26: 1543-1554. doi: 10.1007/s00198-015-3025-1 |
|
[7]
|
Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J]. Osteoporos Int, 2019, 30: 3-44. doi: 10.1007/s00198-018-4704-5 |
|
[8]
|
Genant HK, Wu CY, van Kuijk C, et al. Vertebral fracture assessment using a semiquantitative technique[J]. J Bone Miner Res, 1993, 8: 1137-1148. doi: 10.1002/jbmr.5650080915 |
|
[9]
|
中华医学会骨质疏松和骨矿盐疾病分会. 骨转换生化标志物临床应用指南[J]. 中华骨质疏松和骨矿盐疾病杂志, 2021, 14: 321-336. https://www.cnki.com.cn/Article/CJFDTOTAL-GUSS202104001.htm |
|
[10]
|
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update[J]. Endocr Pract, 2020, 26: 1-46. |
|
[11]
|
Wilkins Parker LR, Preuss CV. Alendronate[M]. Treasure Island (FL): StatPearls Publishing, 2023. |
|
[12]
|
Hirota Y, Nakagawa K, Isomoto K, et al. Eldecalcitol is more effective in promoting osteogenesis than alfacalci-dol in Cyp27b1-knockout mice[J]. PLoS One, 2018, 13: e0199856. doi: 10.1371/journal.pone.0199856 |
|
[13]
|
Food and Drug Administration. Center for drug evaluation and research[EB/OL]. (2020-11-16)[2023-08-04]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/021318Orig1s054.pdf. |
|
[14]
|
Li N, Cornelissen D, Silverman S, et al. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis[J]. Pharmacoeconomics, 2021, 39: 181-209. doi: 10.1007/s40273-020-00965-9 |
|
[15]
|
李梅, 章振林, 夏维波. 骨质疏松症药物治疗的必由之路: 长程序贯治疗[J]. 中华骨质疏松和骨矿盐疾病杂志, 2021, 14: 441-446. https://www.cnki.com.cn/Article/CJFDTOTAL-GUSS202105001.htm |
|
[16]
|
中华医学会骨质疏松和骨矿盐疾病分会. 骨质疏松性椎体压缩性骨折诊疗与管理专家共识[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11: 425-437. https://www.cnki.com.cn/Article/CJFDTOTAL-GUSS201805002.htm |
|
[17]
|
国务院办公厅. 国务院办公厅关于推进分级诊疗制度建设的指导意见[EB/OL]. (2015-09-08)[2023-08-04]. https://www.gov.cn/zhengce/content/2015-09/11/content_10158.htm. |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
